Compare LKFN & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | BBNX |
|---|---|---|
| Founded | 1872 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 493.1M |
| IPO Year | 2009 | N/A |
| Metric | LKFN | BBNX |
|---|---|---|
| Price | $55.50 | $10.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $67.00 | $26.22 |
| AVG Volume (30 Days) | 134.5K | ★ 1.1M |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $985,000.00 | N/A |
| Revenue This Year | $15.08 | $34.99 |
| Revenue Next Year | $5.18 | $34.47 |
| P/E Ratio | $13.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $50.00 | $8.89 |
| 52 Week High | $69.38 | $32.71 |
| Indicator | LKFN | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 37.36 | 34.22 |
| Support Level | N/A | $9.91 |
| Resistance Level | $60.60 | $15.53 |
| Average True Range (ATR) | 1.46 | 0.64 |
| MACD | -0.19 | 0.21 |
| Stochastic Oscillator | 26.14 | 35.51 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.